Peripheral Dopamine Receptors
Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine cha...
Gespeichert in:
Veröffentlicht in: | American journal of hypertension 1990-06, Vol.3 (6-Pt-2), p.25S-28S |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 28S |
---|---|
container_issue | 6-Pt-2 |
container_start_page | 25S |
container_title | American journal of hypertension |
container_volume | 3 |
creator | Kohli, J D |
description | Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine characterizes the DA1 receptor while the reverse order: apomorphine > dipropyl dopamine ≥ dopamine >>> fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S |
doi_str_mv | 10.1093/ajh/3.6.25S |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79932719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79932719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</originalsourceid><addsrcrecordid>eNo9kEtLw0AUhQdRaq2uXBe6ciNp5z2dpdZHhVJFK4ib4WZyQ1PTJs6koP_eSEtXd_F9nMM9hFwyOmTUihGsliMx1EOu3o5Il1nJEsO5OiZdOrYqMVSzU3IW44pSKrVmHdLhTAoxVl3Sf8FQ1EsMUA7uqhrWxQYHr-ixbqoQz8lJDmXEi_3tkfeH-8VkmsyeH58mN7PECy2bBARKAypTAJyi8QigrLSp5ZmlQqeUewq5byszzLyiPPfe5j5FrTLjuRY9crXLrUP1vcXYuHURPZYlbLDaRmesFdww24rXO9GHKsaAuatDsYbw6xh1_2O4dgwnnHbtGK3d38du0zVmB3f_fcuTHS9igz8HDOHLaSOMctOPT6cXc3k7l8Ldij8T1Wkt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79932719</pqid></control><display><type>article</type><title>Peripheral Dopamine Receptors</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><creator>Kohli, J D</creator><creatorcontrib>Kohli, J D</creatorcontrib><description>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine characterizes the DA1 receptor while the reverse order: apomorphine > dipropyl dopamine ≥ dopamine >>> fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1093/ajh/3.6.25S</identifier><identifier>PMID: 2143385</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Animals ; Blood Pressure - drug effects ; Blood Vessels - metabolism ; Chemical Phenomena ; Chemistry ; CY 208 ; DA1/DA2 subtypes ; dihydrexidine ; Dopamine - pharmacology ; Humans ; Indoles - pharmacology ; Peripheral dopamine receptors ; Phenanthridines - pharmacology ; Receptors, Dopamine - metabolism ; Receptors, Dopamine - physiology ; Receptors, Dopamine D1 ; Receptors, Dopamine D2 ; structure activity relationships ; Structure-Activity Relationship ; Vasodilation - physiology</subject><ispartof>American journal of hypertension, 1990-06, Vol.3 (6-Pt-2), p.25S-28S</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2143385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kohli, J D</creatorcontrib><title>Peripheral Dopamine Receptors</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine characterizes the DA1 receptor while the reverse order: apomorphine > dipropyl dopamine ≥ dopamine >>> fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Vessels - metabolism</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>CY 208</subject><subject>DA1/DA2 subtypes</subject><subject>dihydrexidine</subject><subject>Dopamine - pharmacology</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Peripheral dopamine receptors</subject><subject>Phenanthridines - pharmacology</subject><subject>Receptors, Dopamine - metabolism</subject><subject>Receptors, Dopamine - physiology</subject><subject>Receptors, Dopamine D1</subject><subject>Receptors, Dopamine D2</subject><subject>structure activity relationships</subject><subject>Structure-Activity Relationship</subject><subject>Vasodilation - physiology</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLw0AUhQdRaq2uXBe6ciNp5z2dpdZHhVJFK4ib4WZyQ1PTJs6koP_eSEtXd_F9nMM9hFwyOmTUihGsliMx1EOu3o5Il1nJEsO5OiZdOrYqMVSzU3IW44pSKrVmHdLhTAoxVl3Sf8FQ1EsMUA7uqhrWxQYHr-ixbqoQz8lJDmXEi_3tkfeH-8VkmsyeH58mN7PECy2bBARKAypTAJyi8QigrLSp5ZmlQqeUewq5byszzLyiPPfe5j5FrTLjuRY9crXLrUP1vcXYuHURPZYlbLDaRmesFdww24rXO9GHKsaAuatDsYbw6xh1_2O4dgwnnHbtGK3d38du0zVmB3f_fcuTHS9igz8HDOHLaSOMctOPT6cXc3k7l8Ldij8T1Wkt</recordid><startdate>19900601</startdate><enddate>19900601</enddate><creator>Kohli, J D</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900601</creationdate><title>Peripheral Dopamine Receptors</title><author>Kohli, J D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Vessels - metabolism</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>CY 208</topic><topic>DA1/DA2 subtypes</topic><topic>dihydrexidine</topic><topic>Dopamine - pharmacology</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Peripheral dopamine receptors</topic><topic>Phenanthridines - pharmacology</topic><topic>Receptors, Dopamine - metabolism</topic><topic>Receptors, Dopamine - physiology</topic><topic>Receptors, Dopamine D1</topic><topic>Receptors, Dopamine D2</topic><topic>structure activity relationships</topic><topic>Structure-Activity Relationship</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kohli, J D</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kohli, J D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral Dopamine Receptors</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>1990-06-01</date><risdate>1990</risdate><volume>3</volume><issue>6-Pt-2</issue><spage>25S</spage><epage>28S</epage><pages>25S-28S</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><abstract>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine characterizes the DA1 receptor while the reverse order: apomorphine > dipropyl dopamine ≥ dopamine >>> fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>2143385</pmid><doi>10.1093/ajh/3.6.25S</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0895-7061 |
ispartof | American journal of hypertension, 1990-06, Vol.3 (6-Pt-2), p.25S-28S |
issn | 0895-7061 1941-7225 |
language | eng |
recordid | cdi_proquest_miscellaneous_79932719 |
source | MEDLINE; Oxford University Press Journals Digital Archive Legacy |
subjects | Animals Blood Pressure - drug effects Blood Vessels - metabolism Chemical Phenomena Chemistry CY 208 DA1/DA2 subtypes dihydrexidine Dopamine - pharmacology Humans Indoles - pharmacology Peripheral dopamine receptors Phenanthridines - pharmacology Receptors, Dopamine - metabolism Receptors, Dopamine - physiology Receptors, Dopamine D1 Receptors, Dopamine D2 structure activity relationships Structure-Activity Relationship Vasodilation - physiology |
title | Peripheral Dopamine Receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A33%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20Dopamine%20Receptors&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Kohli,%20J%20D&rft.date=1990-06-01&rft.volume=3&rft.issue=6-Pt-2&rft.spage=25S&rft.epage=28S&rft.pages=25S-28S&rft.issn=0895-7061&rft.eissn=1941-7225&rft_id=info:doi/10.1093/ajh/3.6.25S&rft_dat=%3Cproquest_cross%3E79932719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79932719&rft_id=info:pmid/2143385&rfr_iscdi=true |